Industry updates from the field of stem cell research and regenerative medicine in August 2023
Abstract
Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in August 2023.
Tweetable abstract
Regenerative medicine industry news digest, August 2023
References
- 1. BlueRock Therapeutics. BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies (2023). www.bluerocktx.com/bluerock-therapeutics-and-bit-bio-announce-collaboration-and-option-agreement-for-the-discovery-and-manufacture-of-regulatory-t-cell-treg-based-therapies/
- 2. CARsgen Therapeutics. CARsgen Collaborates with Moderna to Evaluate CT041 in Combination with an mRNA Cancer Vaccine (2023). www.carsgen.com/en/news/2023-08-21/
- 3. CytoMed Therapeutics. CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency (2023). https://investor.cytomed.sg/news-and-events/news/news-details/2023/CytoMed-Therapeutics-Announces-China-Research-Collaboration-to-Enhance-its-Allogeneic-CAR--T-In-Vivo-Persistency/default.aspx
- 4. XNK Therapeutics. XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML) (2023). https://xnktherapeutics.com/en/xnk-therapeutics-enters-into-research-collaboration-with-karolinska-university-hospital-in-acute-myeloid-leukemia-aml/
- 5. Cellares. Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform (2023). www.cellares.com/news/cellares-announces-bristol-myers-squibb-has-joined-technology-adoption-partnership-program-to-evaluate-automated-manufacturing-of-car-t-cell-therapy-on-the-cell-shuttle-platform/
- 6. PR Newswire. GenScript Biotech and T-MAXIMUM Biotech Form Strategic Alliance on cGMP sgRNA (2023). www.prnewswire.com/news-releases/genscript-biotech-and-t-maximum-biotech-form-strategic-alliance-on-cgmp-sgrna-301897032.html
- 7. BlueRock Therapeutics. BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint (2023). www.bluerocktx.com/bluerocks-phase-i-study-with-bemdaneprocel-in-patients-with-parkinsons-disease-meets-primary-endpoint/
- 8. NCT04802733. Phase I Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease (2023). www.clinicaltrials.gov/study/NCT04802733
- 9. NCT05897957. Continued Evaluation of Patients with Parkinson's Disease Who Previously Received BRT-DA01 (2023). www.clinicaltrials.gov/study/NCT05897957
- 10. Anixa Biosciences. Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial (2023). https://ir.anixa.com/press-releases/detail/1021/anixa-biosciences-announces-treatment-of-third-patient-in
- 11. NCT05316129. Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer (2023). www.clinicaltrials.gov/study/NCT05316129
- 12. CARsgen Therapeutics. CARsgen Initiates Phase II Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S (2023). www.carsgen.com/en/news/2023-05-18/
- 13. NCT04400383. Clinical Trial to Evaluate AB011 Injection in Patients with CLDN18.2-positive Advanced Solid Tumors (2023). www.clinicaltrials.gov/study/NCT04400383
- 14. PR Newswire. Aegle Therapeutics Corp. Announces First Patient Dosed in Phase I/IIa Clinical Trial Administering a Novel Extracellular Vesicle Therapy (2023). www.prnewswire.com/news-releases/aegle-therapeutics-corp-announces-first-patient-dosed-in-phase-12a-clinical-trial-administering-a-novel-extracellular-vesicle-therapy-301901638.html
- 15. NCT05078385. Safety of Extracellular Vesicles for Burn Wounds (2023). http://www.clinicaltrials.gov/study/NCT05078385
- 16. Arcellx. Arcellx Announces Partial Clinical Hold Lifted On IMMagine-1 Phase II Clinical Program And Reports Second Quarter Financial Results (2023). https://ir.arcellx.com/news/news-details/2023/Arcellx-Announces-Partial-Clinical-Hold-Lifted-on-iMMagine-1-Phase-2-Clinical-Program-and-Reports-Second-Quarter-Financial-Results/default.aspx
- 17. NCT05396885. Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1) (2023). https://classic.clinicaltrials.gov/ct2/show/NCT05396885
- 18. Aspen Neuroscience. Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson's Disease (2023). https://aspenneuroscience.com/aspen-neuroscience-announces-fda-clearance-of-investigational-new-drug-application-for-anpd001-autologous-cell-therapy-for-the-treatment-of-parkinsons-disease/
- 19. ImmPACT Bio USA. Announces FDA Clearance of IND Application for Bispecific CD19/CD20 CAR T Therapy IMPT-514 for the Treatment of Refractory Systemic Lupus Erythematosus (2023). https://immpact-bio.com/news-and-events/immpact-bio-announces-fda-clearance-of-ind-application-for-bispecific-cd19-cd20-car-t-therapy-impt-514-for-the-treatment-of-refractory-systemic-lupus-erythematosus/
- 20. PR Newswire. Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency (2023). www.prnewswire.com/news-releases/approval-of-an-orphan-disease-application-for-its-lead-product-the-cellspan-esophageal-implant-by-the-european-medicines-agency-301905136.html
- 21. Kerecis. New Kerecis Medical-Fish-Skin Product Gets Quick Approval from Medicare Administrative Contractors (2023). www.kerecis.com/new-kerecis-product-gets-quick-approval-from-medicare-administrative-contractors/
- 22. Nexcella. U.S. Food and Drug Administration Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Myeloma (2023). https://nexcella.com/2023/08/23/u-s-food-and-drug-administration-approves-orphan-drug-designation-for-nxc-201-as-a-treatment-for-multiple-myeloma/
- 23. Nexcella. NXC-201 (Formerly HBI0101) Multiple Myeloma (2023). www.clinicaltrials.gov/study/NCT04720313
- 24. Oricell Therapeutics. Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact (2023). www.oricell.com/en/about/news/192.html
- 25. Mesoblast. Mesoblast Receives Complete Response from U.S. Food and Drug Administration For Biologics License Application For Steroid-Refractory Acute Graft Versus Host Disease In Children (2023). https://investorsmedia.mesoblast.com/static-files/422cd6da-a0b9-49cf-a177-7fd106f111f2
- 26. Cellares. Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization (IDMO) and Pioneering Smart Factory to Meet Global Demand for Life-Saving Cell Therapies (2023). www.cellares.com/news/cellares-raises-255m-series-c-to-launch-first-integrated-development-and-manufacturing-organization-idmo-and-pioneering-smart-factory-to-meet-global-demand-for-life-saving-cell-therapies/
- 27. Gracell Biotechnologies. Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors (2023). https://ir.gracellbio.com/node/8681/pdf
- 28. Kyverna Therapeutics. Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors (2023). https://kyvernatx.com/press-releases/kyverna-therapeutics-extends-series-b-financing-round-to-145-million-and-brings-in-new-investors/
- 29. . Neuralink nabs $280M after scoring FDA OK to begin human trials of brain implant. Fierce Biotech (2023). www.fiercebiotech.com/medtech/neuralink-nabs-280m-after-scoring-fda-ok-begin-human-trials-brain-implant
- 30. Poseida Therapeutics. Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy (2023). https://investors.poseida.com/node/8536/pdf